Paul Ehrlich's magic bullet concept: 100 years of progressKlaus Strebhardt(Goethe University Frankfurt), Axel Ullrich(Max Planck Society)Nature reviews. CancerMay 12, 200810.1038/nrc2394Cited by 1,393SaveCiteExport RISWatch citationsAbstractRelated PapersCan the pharmaceutical industry reduce attrition rates?Ismail Kola, J. Richard Landis|Nature Reviews Drug Discovery|2004|4.1kAnticancer activities of histone deacetylase inhibitorsJessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone|Nature Reviews Drug Discovery|2006|2.9kRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al.|Journal of Clinical Oncology|1998|2.8kIDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaDavid G. Maloney, Antonio J Grillo-López, Christine A. White et al.|Blood|1997|1.7kInhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.Elisabeth Buchdunger, J. Zimmermann, Helmut Mett et al.|PubMed|1996|1.1k